Our resources include slide sets from presentations, speaker meetings, congresses; videos of expert opinions and explanations of the latest data; and downloads of infographics and more.

Explore our resources to learn more about dolutegravir and Dovato (dolutegravir/lamivudine).


Watch experts in HIV share the details of Dovato studies and watch internal and external experts share their opinions on the latest data.


Download bite-size infographics on the latest studies and data to help inform your HIV practice.


Catch up on conference symposia, webinars and meeting presentations and learn more about the latest data for Dovato.

DOVATO (Dolutegravir/lamivudine)

DOVATO (Dolutegravir / lamivudine)

Dovato (dolutegravir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Read more Prescribing information

PM-GB-HVX-WCNT-200021 v2 | June 2021